PMID- 10609762
OWN - NLM
STAT- MEDLINE
DCOM- 20000105
LR  - 20170214
IS  - 0003-3197 (Print)
IS  - 0003-3197 (Linking)
VI  - 50
IP  - 12
DP  - 1999 Dec
TI  - Comparison of 50-mg and 100-mg sustained-release isosorbide mononitrate in the 
      treatment of stable angina pectoris: effects on quality-of-life indices. Dutch 
      Mononitrate Quality of Life (DUMQOL) Study Group.
PG  - 963-9
AB  - High-dosage nitrates are more effective for the management of anginal symptoms 
      but produce more adverse effects, including development of tolerance and the 
      zero-hour effect (rebound angina at the end of the dosing interval). Such effects 
      may reduce the beneficial effect of treatment on quality of life. In a 
      self-controlled, 6-month study, the effects on symptoms and quality of life of 50 
      mg and 100 mg sustained-release isosorbide mononitrate (SR ISMN), administered 
      once daily, on anginal symptoms and quality of life (QOL) were assessed in 453 
      patients with stable angina pectoris. QOL was assessed by means of a test battery 
      based on the Medical Outcomes Short-Form 36 Health Survey and the Angina Pectoris 
      Quality of Life Questionnaire. The internal consistency and reliability of the 
      multiitem scales were estimated by use of Cronbach's alpha coefficient. Based on 
      their improvements in New York Heart Association (NYHA) angina classification, 
      patients who received 100 mg daily showed greater improvement than those who 
      received 50 mgdaily; the mean difference between treatments was consistent with a 
      significantly greater improvement of mobility and angina indices. Adverse 
      effects, as estimated by side-effect index, including rebound angina at times of 
      rest, and by patient compliance rating, differed slightly between the two 
      treatment regimens and were even less problematic with the higher dosage than 
      with the lower dosage. Psychological distress index and life satisfaction scores 
      also were significantly higher with 100 mg than with 50 mg daily. The results of 
      this study suggest that SR ISMN 100 mg once daily provided a better NYHA angina 
      classification than SR ISMN 50 mg did and did not produce further adverse 
      effects. In addition SR ISMN 100 mg improved various QOL indices more than SR 
      ISMN 50 mg did, particularly the mobility index and certain life satisfaction 
      scores, which are the most important indicators of QOL in this category of 
      patients.
FAU - Zwinderman, A H
AU  - Zwinderman AH
AD  - Academic Hospital Leiden, The Netherlands.
FAU - Cleophas, T J
AU  - Cleophas TJ
FAU - van der Sluijs, H
AU  - van der Sluijs H
FAU - Niemeyer, M G
AU  - Niemeyer MG
FAU - Buunk, B P
AU  - Buunk BP
FAU - van der Wall, E E
AU  - van der Wall EE
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Vasodilator Agents)
RN  - IA7306519N (Isosorbide Dinitrate)
RN  - LX1OH63030 (isosorbide-5-mononitrate)
SB  - IM
MH  - Aged
MH  - Angina Pectoris/*drug therapy
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Isosorbide Dinitrate/administration & dosage/*analogs & derivatives/therapeutic 
      use
MH  - Male
MH  - Middle Aged
MH  - *Quality of Life
MH  - Vasodilator Agents/*administration & dosage/therapeutic use
EDAT- 1999/12/28 00:00
MHDA- 1999/12/28 00:01
CRDT- 1999/12/28 00:00
PHST- 1999/12/28 00:00 [pubmed]
PHST- 1999/12/28 00:01 [medline]
PHST- 1999/12/28 00:00 [entrez]
AID - 10.1177/000331979905001201 [doi]
PST - ppublish
SO  - Angiology. 1999 Dec;50(12):963-9. doi: 10.1177/000331979905001201.